A new study published in The Journal of Pain found that cannabidiol (CBD) was ineffective in treating chronic pain. The study analyzed 16 randomized double-blind trials encompassing over 900 participants, and found that CBD yielded no greater pain-relieving effect compared to a placebo. Beyond efficacy concerns, there are also concerns regarding the considerable variability in CBD content among products, with some containing significantly more or less CBD than indicated on their labels; and, in some cases, containing other undisclosed compounds. These findings reiterate the pressing need for a new regulatory framework governing CBD products to ensure the accuracy and purity of these products, and to protect consumer health. Learn more about the necessary regulatory reform by reviewing Aimed Alliance’s Essential Elements of a Regulatory Framework for Consumer Products Containing Cannabis-Derived Ingredients and Intended for Human Ingestion.
Last Updated on April 12, 2024 by Aimed Alliance
